Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lori J Goldstein, MD, PhD
Fox Chase Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- University of Kansas Cancer Center, 4350 Shawnee Mission Pkwy, Suite 1500, Mailstop 6004
Fairway, Kansas, United States
- the Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Weill Cornell Medical College
New York, New York, United States
- Montefiore Medical Center, Mmc Medical Park at Eastchester
The Bronx, New York, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States
- Sara Cannon Research Institute
Nashville, Tennessee, United States
- the Methodist Hospital Research Institute
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2013
- Primary completion
- 31 Mar 2015
- Completion
- 1 Mar 2016
- Last update posted
- 14 May 2021
- Registered enrollment
- 20
- Registry id
- NCT01861054
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.